Submitted:
28 July 2025
Posted:
30 July 2025
You are already at the latest version
Abstract
Keywords:
Introduction
Methods:
Statistical Analysis:
- True Positives (TP) were defined as subjects correctly identified as positive by both the EKG alterations and the blood test.
- False Negatives (FN) were defined as subjects incorrectly identified as negative by the EKG alterations but positive by the blood test.
- True Negatives (TN) were defined as subjects correctly identified as negative by both the EKG alterations and the blood test.
- False Positives (FP) were defined as subjects incorrectly identified as positive by the EKG alterations but negative by the blood test.
Results:
| Causes | Cases |
| Hyperparathyroidism | 17 |
| History of Malignant Tumor | 16 |
| Renal Failure | 16 |
| Acidosis | 12 |
| Bone Metabolism Disorder | 6 |
| None | 10 |

| QT(ms) | QTc(ms) | QTm (ms) | |
| Normocalcemia | 380.6± 75.5 | 415.7±57.1 | 270.6±27.0 |
| Hypercalcemia | 340.5± 15.4 | 404.2±78.4 | 226.6±23.4 |
| P-value | <0.01 | <0.01 | <0.01 |
| Characteristic T-Waves alteration | QTm≤240ms | QT≤340ms | QTc≤340ms | |
| Normocalcemia | 14.64% (14/956) | 2.72% (26/956) | 5.4.% (52/956) | 0.21% (2/956) |
| Hypercalcemia | 78.13% (50/64) | 68.75% (44/64) | 48.44% (31/64) | 10.94% (7/64) |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 |
Discussion
References
- Bartkiewicz, P.; Kunachowicz, D.; Filipski, M.; Stebel, A.; Ligoda, J.; Rembialkowska, N. Hypercalcemia in Cancer: Causes, Effects, and Treatment Strategies. Cells. 2024, 13. [Google Scholar] [CrossRef] [PubMed]
- Izzedine, H.; Attieh, R.M.; Begum, F.; Cheung, Y.M.; Jhaveri, K.D. Hypercalcemia of malignancy: Cancer treatment can be a cause as well. Clin Nephrol. 2024, 102, 181–184. [Google Scholar] [CrossRef] [PubMed]
- Walker, M.D.; Shane, E. Hypercalcemia: A Review. JAMA. 2022, 328, 1624–1636. [Google Scholar] [CrossRef] [PubMed]
- Pepe, J.; Magna, A.; Sonato, C.; Sgreccia, A.; Colangelo, L.; Occhiuto, M.; et al. Twenty-four hour Holter ECG in normocalcemic and hypercalcemic patients with hyperparathyroidism. J Endocrinol Invest. 2024, 47, 1499–1504. [Google Scholar] [CrossRef]
- Sadeghian, G.; Ziaei, H.; Sadeghi, M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singap. 2008, 37, 916–918. [Google Scholar] [CrossRef]
- Kazama, I. High-calcium exposure to frog heart: a simple model representing hypercalcemia-induced ECG abnormalities. J Vet Med Sci. 2017, 79, 71–75. [Google Scholar] [CrossRef]
- Chorin, E.; Rosso, R.; Viskin, S. Electrocardiographic Manifestations of Calcium Abnormalities. Ann Noninvasive Electrocardiol. 2016, 21, 7–9. [Google Scholar] [CrossRef]
- Tse, G.; Chan, Y.W.; Keung, W.; Yan, B.P. Electrophysiological mechanisms of long and short QT syndromes. Int J Cardiol Heart Vasc. 2017, 14, 8–13. [Google Scholar] [CrossRef]
- Malik, M. Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation. Drug Saf. 2016, 39, 647–659. [Google Scholar] [CrossRef]
- Tonon, C.R.; Silva, T.; Pereira, F.W.L.; Queiroz, D.A.R.; Junior, E.L.F.; Martins, D.; et al. A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia. Med Sci Monit. 2022, 28, e935821. [Google Scholar] [CrossRef]
- Carsote, M.; Nistor, C.; Gheorghe, A.M.; Sima, O.C.; Trandafir, A.I.; Nistor, T.V.I.; et al. Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, MEN1 Gene-Related Tumors, and Insulin Resistance. Int J Mol Sci. 2024, 25. [Google Scholar] [CrossRef]
- Fayaz, A.; Shah, A.H.; Khan, M.A.; Parveen, S. Multiple Myeloma Presenting as Hypercalcemia-Induced Acute Severe Pancreatitis: A Case Report. Gastro Hep Adv. 2025, 4, 100549. [Google Scholar] [CrossRef]
- Nahass, M.; Sharma, R.; Penn, J. Hypercalcemia-induced pancreatitis presenting with acute ST-elevations mimicking a myocardial infarction. Am J Emerg Med. 2016, 34, 1187 e1-2. [Google Scholar] [CrossRef] [PubMed]
- Sonoda, K.; Watanabe, H.; Hisamatsu, T.; Ashihara, T.; Ohno, S.; Hayashi, H.; et al. High Frequency of Early Repolarization and Brugada-Type Electrocardiograms in Hypercalcemia. Ann Noninvasive Electrocardiol. 2016, 21, 30–40. [Google Scholar] [CrossRef] [PubMed]
- Durant, E.; Singh, A. ST elevation due to hypercalcemia. Am J Emerg Med. 2017, 35, 1033 e3-e6. [Google Scholar] [CrossRef]
- Bahadur, K.A.; Johnson, S.; Lentzner, B.; Gangat, M.; Carlson, J.; Balachandar, S. Hypercalcemia, hyperkalemia and supraventricular tachycardia in a patient with subcutaneous fat necrosis. J Pediatr Endocrinol Metab. 2018, 31, 469–472. [Google Scholar] [CrossRef] [PubMed]
- Cheungpasitporn, W.; Jirajariyavej, T.; Chanprasert, S. Rate control medications for atrial fibrillation in the setting of hypercalcemia. Am J Emerg Med. 2011, 29, 830. [Google Scholar] [CrossRef]
- Schutt, R.C.; Bibawy, J.; Elnemr, M.; Lehnert, A.L.; Putney, D.; Thomas, A.S.; et al. Case report: Severe hypercalcemia mimicking ST-segment elevation myocardial infarction. Methodist Debakey Cardiovasc J. 2014, 10, 193–197. [Google Scholar] [CrossRef]
- Schmidt-Lauber, C.; Anneken, L.; Schodel, J. Hypercalcemia mimicking myocardial infarction. Kidney Int. 2019, 96, 1428. [Google Scholar] [CrossRef]
- Nachimuthu, S.; Assar, M.D.; Schussler, J.M. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012, 3, 241–253. [Google Scholar] [CrossRef]
- Cormier, C. Genetic hypercalcemia. Joint Bone Spine. 2019, 86, 459–466. [Google Scholar] [CrossRef]
- Dauber, A.; Nguyen, T.T.; Sochett, E.; Cole, D.E.; Horst, R.; Abrams, S.A.; et al. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab. 2012, 97, E268–E274. [Google Scholar] [CrossRef]
- De Paolis, E.; Scaglione, G.L.; De Bonis, M.; Minucci, A.; Capoluongo, E. CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype. Clin Chem Lab Med. 2019, 57, 1650–1667. [Google Scholar] [CrossRef]
- Lenherr-Taube, N.; Young, E.J.; Furman, M.; Elia, Y.; Assor, E.; Chitayat, D.; et al. Mild Idiopathic Infantile Hypercalcemia-Part 1: Biochemical and Genetic Findings. J Clin Endocrinol Metab. 2021, 106, 2915–2937. [Google Scholar] [CrossRef]
is greater than that between the back branch and the horizontal baseline
. The peak of the T wave appears earlier. The arrow
in the figure represents QTm, which is 160ms (the distance from the starting point of QRS to the vertex of the T wave). The shortening is ≤240ms. The peak of the T wave moves leftward and approaches the QRS wave, which is a typical pattern change of hypercalcemia.
is greater than that between the back branch and the horizontal baseline
. The peak of the T wave appears earlier. The arrow
in the figure represents QTm, which is 160ms (the distance from the starting point of QRS to the vertex of the T wave). The shortening is ≤240ms. The peak of the T wave moves leftward and approaches the QRS wave, which is a typical pattern change of hypercalcemia.



| Positive | Negtive | SUM | ||
| characteristic T-waves alteration | Hypercalcemia | 50 | 14 | 64 |
| Normocalcemia | 26 | 930 | 956 | |
| Sum | 76 | 944 | 1020 | |
| QT≤340ms | Hypercalcemia | 31 | 33 | 64 |
| Normocalcemia | 220 | 736 | 956 | |
| Sum | 76 | 944 | 1020 | |
| QTm≤240ms | Hypercalcemia | 41 | 23 | 64 |
| Normocalcemia | 52 | 904 | 956 | |
| Sum | 76 | 944 | 1020 | |
| QTc≤340ms | Hypercalcemia | 7 | 57 | 64 |
| Normocalcemia | 2 | 954 | 956 | |
| Sum | 76 | 944 | 1020 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).